胰岛素抵抗
脂肪变性
非酒精性脂肪肝
脂肪肝
细胞凋亡
生物
ASK1
内分泌学
癌症研究
内科学
激酶
蛋白激酶A
细胞生物学
胰岛素
医学
丝裂原活化蛋白激酶激酶
疾病
生物化学
作者
Peng Sun,Qiang Zeng,Daqing Cheng,Kuo Zhang,Jilin Zheng,Yupeng Liu,Yufeng Yuan,Yi‐Da Tang
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2018-05-05
卷期号:68 (6): 2212-2229
被引量:19
摘要
The rapidly increasing prevalence of metabolic disorders associated with nonalcoholic fatty liver disease (NAFLD) warrants further study of the underlying mechanisms to identify key regulators as targets for the development of therapeutic interventions. Caspase recruitment domain protein 6 (Card6), as a member of the CARD family that regulates cell death and immunity, may potentially control this process. Indeed, Card6 down‐regulation was found to be closely associated with the fatty livers observed in NAFLD patients, obese mice, and a palmitate‐treated hepatocyte model. Gain‐of‐function and loss‐of‐function Card6 mouse models demonstrated that Card6 protected mice from insulin resistance, hepatic steatosis, and inflammatory responses upon high‐fat diet administration. Mechanistically, Card6 interacted with and inhibited apoptosis signal–regulating kinase 1 (Ask1) and its subsequent downstream c‐Jun N‐terminal kinase/p38 signaling. Furthermore, Ask1 was sufficient to mediate Card6 function, and the interaction between Ask1 and Card6 was absolutely required for Card6 function in vivo . Adenovirus‐mediated Card6 overexpression in the liver effectively ameliorated insulin resistance and hepatic steatosis in ob/ob mice. Therefore, we identified Card6 as an important negative regulator in NAFLD. Conclusion: Targeting Ask1 by Card6 may be a good strategy to develop a therapeutic method against NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI